

Linda M S Resar

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4313128/linda-m-s-resar-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

88

papers

3,012

citations

30

h-index

54

g-index

95

ext. papers

3,418

ext. citations

4.6

avg, IF

4.85

L-index

#	Paper	IF	Citations
88	The High Mobility Group A1 Chromatin Regulator Drives Immune Evasion during MPN Progression By Repressing Genes Involved in Antigen Presentation and Immune Attack. <i>Blood</i> , 2021 , 138, 2546-2546 ^{2.2}		
87	Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia. <i>Pediatric Blood and Cancer</i> , 2021 , 68, e28888	3	0
86	Conditional reprogramming culture conditions facilitate growth of lower-grade glioma models. <i>Neuro-Oncology</i> , 2021 , 23, 770-782	1	3
85	Perioperative Management of Patients for Whom Transfusion Is Not an Option. <i>Anesthesiology</i> , 2021 , 134, 939-948	4.3	1
84	Integrative molecular characterization of pediatric spinal ependymoma: the UK Children's Cancer and Leukaemia Group study. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab043	0.9	2
83	Doubling up on function: dual-specificity tyrosine-regulated kinase 1A (DYRK1A) in B cell acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	2
82	Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. <i>Blood Advances</i> , 2020 , 4, 2567-2576	7.8	19
81	High mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 179, 25-35	4.4	4
80	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. <i>Cancer Research</i> , 2019 , 79, 4326-4330	10.1	57
79	Greater anemia tolerance among hospitalized females compared to males. <i>Transfusion</i> , 2019 , 59, 2551-2558	2.9	4
78	Genetic Engineering of Primary Mouse Intestinal Organoids Using Magnetic Nanoparticle Transduction Viral Vectors for Frozen Sectioning. <i>Journal of Visualized Experiments</i> , 2019 ,	1.6	3
77	The High Mobility Group A1 Chromatin Regulator Is Required for Pathologic Megakaryocyte Development and Progression to Myelofibrosis in JAK2V617F Murine Models. <i>Blood</i> , 2019 , 134, 472-472 ^{2.2}		
76	Approaches to Bloodless Surgery for Oncology Patients. <i>Hematology/Oncology Clinics of North America</i> , 2019 , 33, 857-871	3.1	5
75	Preoperative treatment of anemia and outcomes in surgical Jehovah's Witness patients. <i>American Journal of Hematology</i> , 2019 , 94, E55-E58	7.1	6
74	PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis. <i>Prostate</i> , 2018 , 78, 547-559	4.2	8
73	Lessons from the Crypt: HMGA1-Amping up Wnt for Stem Cells and Tumor Progression. <i>Cancer Research</i> , 2018 , 78, 1890-1897	10.1	24
72	High Mobility Group A1 Chromatin Remodeling Proteins Amplify Inflammatory Networks to Drive Leukemic Transformation in Chronic Myeloproliferative Neoplasia in Humans and JAK2V617F Transgenic Mouse Models. <i>Blood</i> , 2018 , 132, 102-102	2.2	

71	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- β Superfamily. <i>Cell Systems</i> , 2018 , 7, 422-437.e7	10.6	85
70	HMGA1 amplifies Wnt signalling and expands the intestinal stem cell compartment and Paneth cell niche. <i>Nature Communications</i> , 2017 , 8, 15008	17.4	34
69	Hmga1 deficiency: "SAC-King" the SAC genes to incite chromosomal instability. <i>Cell Cycle</i> , 2017 , 16, 17-18.7	1.7	0
68	Transcriptomic analysis in pediatric spinal ependymoma reveals distinct molecular signatures. <i>Oncotarget</i> , 2017 , 8, 115570-115581	3.3	5
67	STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)-STAT3 pathway. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2681-4	1.9	10
66	Symptomatic Avascular Necrosis: An Understudied Risk Factor for Acute Care Utilization by Patients with SCD. <i>Southern Medical Journal</i> , 2016 , 109, 519-24	0.6	5
65	High Mobility Group A1/2 Chromatin Remodeling Proteins Associate with Polycythemia Vera Transformation to Acute Leukemia in Humans and a JAK2 V617F Transgenic Mouse Model. <i>Blood</i> , 2016 , 128, 1958-1958	2.2	
64	High Mobility Group A1 Chromatin Remodeling Protein Regulates Self-Renewal, Niche Formation, and Regenerative Function in Adult Stem Cells through Wnt/ β Catenin Signaling. <i>Blood</i> , 2016 , 128, 2647-2647	2.2	1
63	Patent foramen ovale in adults with sickle cell disease and stroke. <i>American Journal of Hematology</i> , 2016 , 91, E358-60	7.1	3
62	Fecal Metabolome in Hmga1 Transgenic Mice with Polyposis: Evidence for Potential Screen for Early Detection of Precursor Lesions in Colorectal Cancer. <i>Journal of Proteome Research</i> , 2016 , 15, 4176-4187	5.6	7
61	Bloodless medicine: current strategies and emerging treatment paradigms. <i>Transfusion</i> , 2016 , 56, 2637-2647	2.9	19
60	How I treat priapism. <i>Blood</i> , 2015 , 125, 3551-8	2.2	32
59	Characterizing metabolic changes in human colorectal cancer. <i>Analytical and Bioanalytical Chemistry</i> , 2015 , 407, 4581-95	4.4	34
58	Hemoglobin thresholds for transfusion in pediatric patients at a large academic health center. <i>Transfusion</i> , 2015 , 55, 2890-7	2.9	13
57	Efficacy of education followed by computerized provider order entry with clinician decision support to reduce red blood cell utilization. <i>Transfusion</i> , 2015 , 55, 1628-36	2.9	34
56	HMGA1 drives metabolic reprogramming of intestinal epithelium during hyperproliferation, polyposis, and colorectal carcinogenesis. <i>Journal of Proteome Research</i> , 2015 , 14, 1420-31	5.6	23
55	A Novel Feed-Forward Loop Involving the High Mobility Group A1 (HMGA1) Chromatin Remodeling Protein and cMYC in Acute Myeloid Leukemia Is Targeted By JQ1. <i>Blood</i> , 2015 , 126, 2466-2466	2.2	
54	The high mobility group A1 molecular switch: turning on cancer - can we turn it off?. <i>Expert Opinion on Therapeutic Targets</i> , 2014 , 18, 541-53	6.4	27

53	Hydroxyurea therapy for priapism prevention and erectile function recovery in sickle cell disease: a case report and review of the literature. <i>International Urology and Nephrology</i> , 2014 , 46, 1733-1736	2.3	16
52	Bloodless medicine: what to do when you can't transfuse. <i>Hematology American Society of Hematology Education Program</i> , 2014 , 2014, 553-8	3.1	21
51	Hitting the bull's eye: targeting HMGA1 in cancer stem cells. <i>Expert Review of Anticancer Therapy</i> , 2014 , 14, 23-30	3.5	14
50	Risk-adjusted clinical outcomes in patients enrolled in a bloodless program. <i>Transfusion</i> , 2014 , 54, 2668-2709	4.1	
49	Nanoparticle delivery of inhibitory signal transducer and activator of transcription 3 G-quartet oligonucleotides blocks tumor growth in HMGA1 transgenic model of T-cell leukemia. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1194-7	1.9	12
48	Patent Foramen Ovale in Adult Patients with Sickle Cell Disease and Stroke. <i>Blood</i> , 2014 , 124, 4084-4084	2.2	
47	Essential Thrombocytosis: Redefinition in the Genomic Era. <i>Blood</i> , 2014 , 124, 3205-3205	2.2	
46	Avascular Necrosis: An Understudied Risk Factor for Acute Care Utilization By Patients with Sickle Cell Disease. <i>Blood</i> , 2014 , 124, 2709-2709	2.2	
45	High Mobility Group A1 (HMGA1) Chromatin Remodeling Protein Mediates Crosstalk Between Acute Myeloid Leukemia Blasts & the Tumor Microenvironment. <i>Blood</i> , 2014 , 124, 3564-3564	2.2	1
44	A novel method of data analysis for utilization of red blood cell transfusion. <i>Transfusion</i> , 2013 , 53, 3052-3052	2.9	73
43	HMGA1 overexpression correlates with relapse in childhood B-lineage acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2565-7	1.9	23
42	Inactivation of the Cdkn2a locus cooperates with HMGA1 to drive T-cell leukemogenesis. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1762-8	1.9	17
41	More common than you think: common variable immune deficiency. <i>Case Reports in Hematology</i> , 2013 , 2013, 153767	0.7	1
40	Patent foramen ovale in patients with sickle cell disease and stroke: case presentations and review of the literature. <i>Case Reports in Hematology</i> , 2013 , 2013, 516705	0.7	11
39	HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells. <i>PLoS ONE</i> , 2013 , 8, e63419	3.7	88
38	The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma. <i>Pancreatology</i> , 2012 , 12, 372-9	3.8	27
37	HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. <i>PLoS ONE</i> , 2012 , 7, e30034	3.7	81
36	HMGA1 reprograms somatic cells into pluripotent stem cells by inducing stem cell transcriptional networks. <i>PLoS ONE</i> , 2012 , 7, e48533	3.7	69

35	High mobility group A1 and cancer: potential biomarker and therapeutic target. <i>Histology and Histopathology</i> , 2012 , 27, 567-79	1.4	57
34	Polycythemia Vera: Redefinition in the Genomic Era. <i>Blood</i> , 2012 , 120, 1754-1754	2.2	
33	HMGA1, a Factor Enriched in Hematopoietic Stem Cells, Embryonic Stem Cells, and Hematologic Malignancy, Enhances Cellular Reprogramming to a Pluripotent Stem-Like Cell.. <i>Blood</i> , 2012 , 120, 2323-2323	2.2	
32	Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. <i>Cell Research</i> , 2011 , 21, 518-29	24.7	363
31	HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis. <i>BMC Genomics</i> , 2011 , 12, 549	4.5	61
30	Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1999-2006	1.9	38
29	AKNA: another AT-hook transcription factor "hooking-up" with inflammation. <i>Cell Research</i> , 2011 , 21, 1528-30	24.7	17
28	HMGA1 Drives Inflammatory Pathways, Cell Cycle Progression, and Embryonic Stem Cell Genes During Leukemic Transformation. <i>Blood</i> , 2011 , 118, 1371-1371	2.2	
27	The high mobility group A1 gene: transforming inflammatory signals into cancer?. <i>Cancer Research</i> , 2010 , 70, 436-9	10.1	88
26	HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. <i>Modern Pathology</i> , 2010 , 23, 98-104	9.8	62
25	Low dose, oral epsilon aminocaproic acid for renal papillary necrosis and massive hemorrhage in hemoglobin SC disease. <i>Pediatric Blood and Cancer</i> , 2010 , 54, 148-50	3	4
24	Ghosal hematodiaphyseal dysplasia: a rare cause of a myelophthisic anemia. <i>Pediatric Blood and Cancer</i> , 2010 , 55, 1187-90	3	12
23	Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. <i>Molecular Cancer Research</i> , 2009 , 7, 1803-12	6.6	55
22	Inactivation of the INK4A/ARF (CDKN2) locus Cooperates with HMGA1 in T-Cell Leukemogenesis.. <i>Blood</i> , 2009 , 114, 3969-3969	2.2	
21	Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 2090-5	6.1	28
20	HMGA2 participates in transformation in human lung cancer. <i>Molecular Cancer Research</i> , 2008 , 6, 743-50	6.6	107
19	The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies?. <i>Cancer Research</i> , 2008 , 68, 10121-7	10.1	82
18	Pulsed-dosing with oral sodium phenylbutyrate increases hemoglobin F in a patient with sickle cell anemia. <i>Pediatric Blood and Cancer</i> , 2008 , 50, 357-9	3	15

17	The HMGA1a-STAT3 axis: an Achilles Heel for Hematopoietic Malignancies Overexpressing HMGA1a?. <i>Blood</i> , 2008 , 112, 3810-3810	2.2	0
16	Flavopiridol Down-Regulates Genes Involved in Cell Cycle Regulation and Tumor Progression in Adults with Refractory or Poor-Risk Acute Leukemia.. <i>Blood</i> , 2008 , 112, 953-953	2.2	1
15	The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. <i>Cancer Research</i> , 2007 , 67, 3998-4004	10.1	61
14	Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: a retrospective cohort study of 137 children with sickle cell anemia. <i>Journal of Pediatrics</i> , 2006 , 149, 710-2	3.6	113
13	STAT3: A Direct HMGA1 Gene Target Important in Lymphoid Malignancy.. <i>Blood</i> , 2006 , 108, 2222-2222	2.2	
12	The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. <i>Cancer Research</i> , 2004 , 64, 3371-5	10.1	102
11	Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation. <i>Oncogene</i> , 2004 , 23, 4466-76	9.2	44
10	High mobility group protein HMGI(Y) enhances tumor cell growth, invasion, and matrix metalloproteinase-2 expression in prostate cancer cells. <i>Prostate</i> , 2004 , 60, 160-7	4.2	46
9	HMG-I/Y is a c-Jun/activator protein-1 target gene and is necessary for c-Jun-induced anchorage-independent growth in Rat1a cells. <i>Molecular Cancer Research</i> , 2004 , 2, 305-14	6.6	24
8	HMG-I/Y Is a c-Jun/Activator Protein-1 Target Gene and Is Necessary for c-Jun-Induced Anchorage-Independent Growth in Rat1a Cells. <i>Molecular Cancer Research</i> , 2004 , 2, 305-314	6.6	26
7	HMG-I/Y in human breast cancer cell lines. <i>Breast Cancer Research and Treatment</i> , 2002 , 71, 181-91	4.4	52
6	Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2002 , 24, 737-41	1.2	30
5	Sequence and analysis of the murine Hmgiy (Hmga1) gene locus. <i>Gene</i> , 2001 , 271, 51-8	3.8	29
4	HMG-I/Y, a new c-Myc target gene and potential oncogene. <i>Molecular and Cellular Biology</i> , 2000 , 20, 5490-802	4.5	159
3	Neuropsychologic Deficits in Children with Sickle Cell Disease and Cerebral Infarction: Role of Lesion Site and Volume. <i>Child Neuropsychology</i> , 1999 , 5, 92-103	2.7	43
2	Function of the c-Myc oncogenic transcription factor. <i>Experimental Cell Research</i> , 1999 , 253, 63-77	4.2	297
1	Hitting the bullseye: targeting HMGA1 in cancer stem cells. <i>Expert Review of Anticancer Therapy</i> , 2008 , 8, 1-8	3.5	2